ACCESS REALMONEY
Pharmaceuticals
- Article Tools
- Email this Article
- Print this Article
- Rss Feed
- Related Articles
- Wyeth Names CFO
- Sierra Shareholders OK Merger
- Diabetes-Drug Makers Tout Two-Pronged Approach
- Del.icio.us
- Digg
- StumbleUpon
Specialty pharmaceutical company SantarusSNTS gained 10% Friday, following news of a co-promotion agreement with a privately held pharmaceutical company and an analyst upgrade. The San Diego, Calif., company said Thursday after market close that it made an agreement with Victory Pharma regarding Victory's anti-inflammatory drug Naprelan. Santarus said the once-daily tablets are indicated for the treatment of a number of conditions, including arthritis and the relief of mild to moderate pain. The agreement dictates that Santarus will promote the tablets to targeted primary care physicians and will be paid a co-promotion fee as a percentage of net sales generated from those efforts. The company said it will incur incremental expenses associated with the promotion of Naprelan products. Friedman Billings upgraded the company to outperform from market perform on Friday morning. The stock was up 30 cents, or 5.8%, at $5.31 in recent trading Friday afternoon.
Greg Norden will take the post.
The merger with UnitedHealth Group now faces regulators.
Merck and others say DPP-4 inhibitors improve blood-sugar control when added to a standard treatment.
Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.
Catch up on his thinking on the hottest topics of the past week.
Investors will have to deal with a Fed meeting and another flood of earnings and economic data.
Ensco International and Echelon have the potential to move higher in coming days.
See who made what calls.
The addition of video is helping telecom companies compete against cable and satellite companies.
The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.
See who made what calls.
Keep on top of the market and the critical information you need to make more profitable investing decisions.
Sponsored by:
RSS
